Tallal Younis

Prof. Dr. Tallal Younis


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2018 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
IKIman Aftab Khan
Iman Aftab Khan
BYByong Hoon Yoo
Byong Hoon Yoo
MMMichael McPhee
Michael McPhee
OMOlivier Masson
Olivier Masson
ASAlexi Surette
Alexi Surette
KRKirill Rosen
Kirill Rosen
The ability of solid tumor cells to resist anoikis, apoptosis triggered by cell detachment from the extracellular matrix (ECM), is thought to be critical for 3D tumor growth. ErbB2/Her2 oncoprotein is often overproduced by breast tumor cells and blocks their anoikis by partially understood mechanisms. In our effort to understand them better, we observed that detachment of nonmalignant human breast epithelial cells from the ECM upregulates the transcription factor Irf6. Irf6 is thought to play an important role in mammary gland homeostasis and causes apoptosis by unknown mechanisms. We noticed that ErbB2, when overproduced by detached breast epithelial cells, downregulates Irf6. To test whether ErbB2 downregulates Irf6 in human ErbB2-positive breast cancer cells, we examined the effect of ErbB2 inhibitors, such as the anti-ErbB2 antibody trastuzumab or the ErbB2/epidermal growth factor receptor small-molecule inhibitor lapatinib, on Irf6 in these cells. Moreover, we performed Irf6 IHC analysis of tumor samples derived from the locally advanced ErbB2-positive breast cancers before and after neoadjuvant trastuzumab-based therapies. To examine the role of Irf6 in anoikis of nonmalignant and ErbB2-overproducing breast epithelial cells, we studied anoikis after knocking down Irf6 in the former cells by RNA interference and after overproducing Irf6 in the latter cells. To examine the mechanisms by which cell detachment and ErbB2 control Irf6 expression in breast epithelial cells, we tested the effects of genetic and pharmacological inhibitors of the known ErbB2-dependent signaling pathways on Irf6 in these cells. We observed that trastuzumab and lapatinib upregulate Irf6 in ErbB2-positive human breast tumor cells and that neoadjuvant trastuzumab-based therapies tend to upregulate Irf6 in human breast tumors. We found that detachment-induced Irf6 upregulation in nonmalignant breast epithelial cells requires the presence of the transcription factor ∆Np63α and that Irf6 mediates their anoikis. We showed that ErbB2 blocks Irf6 upregulation in ErbB2-overproducing cells by activating the mitogen-activated protein kinases that inhibit ∆Np63α-dependent signals required for Irf6 upregulation. Finally, we demonstrated that ErbB2-driven Irf6 downregulation in ErbB2-overproducing breast epithelial cells blocks their anoikis and promotes their anchorage-independent growth. We have demonstrated that ErbB2 blocks anoikis of breast epithelial cells by downregulating Irf6.

5 August 2016 in Pilot and Feasibility Studies
Verified
Journal Article
Open access
PDF file
Melanie KeatsMelanie Keats
Melanie Keats
Scott A. GrandyScott A. Grandy
Scott A. Grandy
NGNicholas Giacomantonio
Nicholas Giacomantonio
DMDavid MacDonald
David MacDonald
MRMiroslaw Rajda
Miroslaw Rajda
TYTallal Younis
Tallal Younis
Anthracyclines (AC), widely used and effective anticancer agents, are known to induce both acute and chronic declines in cardiovascular health, ranging in severity from asymptomatic, subclinical dysfunction to substantial cardiomyopathy leading to congestive heart failure and death. There is substantial evidence that physical activity, higher levels of cardiorespiratory fitness, and exercise therapy can help prevent cardiovascular disease. Moreover, animal studies have shown that exercise performed concomitantly with AC treatment may attenuate early cardiac damage that results from AC exposure. Our primary objective is to assess the feasibility of a 12-week aerobic exercise training (AET) program in patients receiving AC-based chemotherapy. This is a prospective, single-arm (pre-post-test design), feasibility study of a supervised 12-week progressive, light-to-moderate to moderate-to-vigorous intensity AET program for patients (18–65 years) receiving AC chemotherapeutic treatment for a primary/non-recurrent breast cancer or hematological malignancy. Both feasibility (e.g., participant recruitment, program adherence, safety) and intervention outcome (e.g., biological markers of cardiotoxicity, aerobic capacity, quality of life) measures will be collected. The AET program will include two, 45-min community-based exercise sessions (treadmill or cycle) per week for a total of 12 weeks. All exercise sessions will be supervised by trained exercise specialists. Data from the EXACT study will be evaluated to determine the need to refine patient recruitment methods and general acceptability of the AET program. Preliminary data on the effects of the AET intervention on pertinent cardiac and health outcomes will also be evaluated and used to inform future studies in terms of the most appropriate outcome measure(s) to adopt and sample size estimation. ClinicalTrails.gov, NCT02471053

5 June 2021 in Current Oncology
Verified
Journal Article
Open access
PDF file
SMSally Miller
Sally Miller
Robin UrquhartRobin Urquhart
Robin Urquhart
GKGeorge Kephart
George Kephart
YAYukiko Asada
Yukiko Asada
TYTallal Younis
Tallal Younis
Coordinating breast cancer treatment is a complex task that can overwhelm patients and their support networks. Though the Cancer Patient Navigator (CPN) program in Nova Scotia (NS) provides professional assistance to patients, certain groups of patients may still face barriers to accessing its services. Employing interviews and a modified Delphi approach with CPN participants, this study sought to identify factors associated with the need for navigation to help better target CPN program referrals among breast cancer patients. Six CPNs were recruited directly through the CPN program manager for interviews and surveys. The CPNs identified 27 different factors, which were divided into 4 categories: sociodemographic, psychological, clinical and health systems. While these patient factors (particularly sociodemographic) are not directly modifiable, awareness of their association with the need for navigation could be used to better target patients with a high need for navigation for referral to CPN services.

30 August 2016 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
TYTallal Younis
Tallal Younis
DRD. Rayson
D. Rayson
SJS. Jovanovic
S. Jovanovic
CSC. Skedgel
C. Skedgel

1 June 2005 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
KPK. R. Potvin
K. R. Potvin
TYTallal Younis
Tallal Younis
MSM. Sellon
M. Sellon
PBP. Barnes
P. Barnes
DRD. Rayson
D. Rayson
6070 Background: Trastuzumab is approved for treatment of HER2/neu over-expressing metastatic breast cancer. There is an absence of data on the costs associated with trastuzumab-based treatment strategies in actual clinical practice. This study was undertaken to identify the strategies currently employed in a single Canadian cancer centre and to explore the costs associated with each strategy. Methods: We performed a retrospective review of all patients treated with trastuzumab at our centre since its approval in Canada. Data was collected using pharmacy records in conjunction with patient charts. Fifty-three patients had complete treatment data and were included in the analysis. Treatment strategies were identified based on timing of trastuzumab initiation. Mean number of cycles (1 cycle = trastuzumab weekly x 3, or Q3 weeks x 1), mean cost per patient and total cost were calculated for each strategy. Results: Four strategies were identified: first-line trastuzumab combined with chemotherapy followed by maintenance trastuzumab (T/C - T); first-line monotherapy (T); second-line or beyond combined with chemotherapy (t/c) and second-line or beyond monotherapy (t). The results are summarized in the table below. The costs reflect trastuzumab only and do not include the cost of additional chemotherapy. Only one patient received first-line monotherapy hence values in the table for “T” represent actual costs. Fifty-eight percent of patients who progressed after first-line therapy continued to receive trastuzumab after progression compared to only 33% progressing after second-line therapy. The total cost of treatment for 53 patients thus far is greater than 1.6 million dollars (Cdn.). Conclusions: Our data highlights the potential costs to be faced by health care systems as novel targeted therapies become available. It further emphasizes the importance of identifying optimal treatment strategies using these agents to ensure appropriate resource allocation. No significant financial relationships to disclose.

1 October 2017 in Current Oncology
Verified
Journal Article
Open access
TYTallal Younis
Tallal Younis
CSC. Skedgel
C. Skedgel
The oncology drug review process for public funding in Canada (Figure 1) encompasses both.